Home > Physicians > Medical Education > Med Ed Programs > Myelodysplastic Syndrome: Making Treatment Decisions in an Evolving Field

CME Program

Myelodysplastic Syndrome: Making Treatment Decisions in an Evolving Field

Order CD

http://www.marrow.org/medorder
(no CME credit available)

Faculty

H. Joachim Deeg, M.D., Member, Fred Hutchinson Cancer Research Center and Professor of Medicine, University of Washington, Seattle, Washington

Program Description

The treatment of myelodysplastic syndromes (MDS) has received much attention recently as more has been learned about prognostic indicators and biologic features of the disease, and recent developments on new agents have provided new therapeutic options. H. Joachim Deeg, M.D. will examine the emerging data and provide insight into current treatment strategies, including transplantation: Which risk factors are critical to assess when choosing a therapy? Are there sub-groups for whom there is a standard first-line treatment? How do emerging therapies impact our decision-making for transplantation? How should treatment decisions be affected by age of the patient and quality-of-life issues?

Goal

The goal of this activity is to describe appropriate therapeutic strategies for patients with myelodysplastic syndromes (MDS).

Learning Objectives

Describe advances in classification systems and impact on treatment decisions
Explain current clinical evidence for treatment strategies, including timing of therapy choices, by patient risk sub-groups
List the elements of a successful treatment plan when transplantation is an option
Describe recent advances in the treatment of older patients, including reduced-intensity transplantation
Recognize the importance of quality-of-life issues in decision-making

Target Audience

This activity is intended for hematologists, oncologists and other health professionals who are involved in the treatment of patients with chronic myelogenous leukemia.

Accreditation and Certification

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the:

Medical College of Wisconsin
National Marrow Donor Program^® (NMDP)
Center for International Blood & Marrow Transplant Research ^TM (CIBMTR)

The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this educational activity for a maximum of 1.0 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.

E-mail a Friend

Print this Page

Quick reference referral and post-transplant care guidelines